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CASE REPORT
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A 22-day-old male infant (corrected gestational age 
of 37 5/7 weeks) was brought to the hospital because 
of numerous apneic episodes. He had been born pre-
maturely at 34 4/7 weeks of gestation due to amniotic 
infection syndrome. His birthweight had been 2220 g 
(P25 – 50). Pregnancy, vaginal delivery and adaptation 
had been uncomplicated. The infant received photo-
therapy for neonatal jaundice from day of life (DOL) 
5 to 7. 
The parents described recurrent episodes of aspiration 
since DOL 17, and a one-day history of poor feeding. 
On admission, the infant was sleepy, inactive, and 
showed inappropriate response to handling. Numerous 
apneic episodes were noted. The clinical examination was 
remarkable for jaundice, prolonged capillary refill time 
(3 – 4 seconds), dry mucosal membranes and a sunken 
fontanel. 
Blood cultures were obtained, and empiric treatment 
with amoxicillin and gentamicin was started to treat 
possible bacterial sepsis. Due to poor respiratory effort 
and recurrence of apnea, the boy had to be intubated. 
The initial working hypothesis was late onset sepsis 
or a respiratory viral infection, such as respiratory 
syncytial virus (RSV). Other differential diagnoses 
were also considered: metabolic disease (prolonged 
jaundice), convulsions or energy deficiency as a result 
of poor feeding.
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Except for leukocytosis (leukocyte count 21.84 G/ l, 
neutrophils 7.80 G/ l, lymphocytes 12.19 G/ l) and a pre-
viously known slight increase of liver function tests 
(bilirubin, LDH and GGT), laboratory results (inclu-
ding C-reactive protein, interleukin-6, electrolytes, 
ammonia and renal function tests) were normal. 
A chest radiograph showed bilateral peribronchial 
consolidations suggestive of aspiration pneumo-
nia (Fig. 1). Echocardiography and cranial ultrasound 
examination were also normal. Unblinding of the newborn 
screening test showed normal results.
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One day after admission, a tracheal aspirate sample 
was reported to be positive for Bordetella pertussis. 
Antibiotic therapy was therefore changed to intra-
venous azithromycin 10 mg/kg 24-hourly for 5 days (1). 
Droplet isolation was added to the previously ordered 
contact isolation.
The infant’s mother and sister reported a history 
of coryza and cough over the past 3 weeks. The 
vaccination status of the 4-year-old sister was up 
to date. The infant’s father had received pertussis 
vaccination 6 years ago; the mother’s last booster had 
occurred 10 years ago. She had not been immunized 
during pregnancy. The parents and sister received 
post-exposure prophylaxis (PEP). The mother’s nasal 
swab and blood tests (including blood count, C-reac-
tive protein, electrolytes, coagulation tests, liver and 
renal function) were unremarkable.
In order to protect the other newborns in the ward, 
all staff members who had had contact with the 
patient prior to droplet isolation precautions were 
required to take PEP with oral azithromycin for 5 days 
and to wear a surgical mask during the same time 
period (regardless of their vaccination status). The 
team members who refused PEP were asked to wear 
a surgical mask for 21 days. Because of the high risk 
for the premature babies in our NICU, the baby with 
pertussis was transferred to a pediatric intensive care 
unit (PICU). The infant required respiratory support for 
7
5 days (invasive mechanical ventilation for 2 days, 
CPAP for 1 day and low flow for another 2 days) and 
received caffeine therapy for 12 days. He could be 
discharged after a 20-day hospitalization.
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DISCUSSION Despite a widespread vaccination program, pertussis 
continues to be a common infection in the pediatric 
and adult population worldwide. In 2018, the World 
Health Organization (WHO) reported 151’074 cases 
of pertussis despite an estimated global diphtheria- 
tetanus-pertussis (DTP) vaccine coverage with three 
doses (2) of 86%.
Pertussis is a highly contagious acute respiratory 
disease that is often underdiagnosed. The majority of 
cases (86 – 95%) is caused by Bordetella pertussis with 
the remaining cases being caused by Bordetella para-
pertussis (3 – 5). Bordetella species are gram-nega-
tive, aerobic, encapsulated coccobacilli. Transmission 
occurs via aerosolized respiratory droplets. After an 
incubation period of 4 – 21 days (typically 7 – 10 days), 
symptoms develop and typically last for 6 to 12 weeks 
(sometimes longer).
Classical pertussis, as it is seen in unvaccinated child-
ren, is characterized by three stages: stadium catarrhale 
(similar to a viral upper respiratory infection with mild 
cough and coryza), stadium convulsivum (coughing 
spells of increasing severity with or without post tus-
sive vomiting), and stadium decrementi (decreasing 
severity of the clinical symptoms). In infants younger 
than 3 months, the catarrhal stage can be shorter 
than in older children and can remain unrecognized, 
whereas stadium convulsivum and decrementi are 
usually prolonged (3, 4, 6). 
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Apart from coughing, pertussis in this age group 
often causes apnoea, which can be the first symptom 
of the disease. 18% of infected infants < 12 months of 
age require hospitalization, with apnoea occurring in 
61% and pneumonia occurring in 23% of these cases. 
Many require supplemental oxygen, and some need 
mechanical ventilation because of acute respiratory 
distress syndrome (with or without pulmonary hyper-
tension) or apnoea. Seizures (1%) are also a known 
complication (7). Another well-known finding is severe 
hyperviscosity of the blood due to the pathognomonic 
hyperleukocytosis, which can lead to death in young 
infants (8).
10
Pertussis: transmission and complications  
(graphic designer: Chiara Benetton) (4,7).
Fig. 2 
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The severity of the disease is inversely related to 
the age of the patient. Neonates and toddlers have 
higher morbidity – as described above – and mortality 
rates (3, 9). Apart from the patient’s age, the clinical 
manifestations are influenced by the immunization 
status and – in newborns – the amount of transpla-
centally acquired antibodies. The overall lethality of 
pertussis infection is estimated to be 0,05 per 1’000 
cases. The mortality rate is four times higher in child-
ren from birth to 5 years of age (0,2 deaths per 1’000 
cases) with infants less than 3 months of age being at 
highest risk with about 10 deaths per 1’000 cases (4). 
The burden of the disease calls for preventative 
measures against pertussis in infants, especially in 
newborns. Several strategies have been proposed 
to protect neonates. Maternal vaccination during 
pregnancy is the most effective strategy to date. 
It leads to transplacental transfer of IgG antibodies 
to the fetus. After birth, the neonate receives addi-
tional antibodies, especially of the IgA isotype, via 
breastmilk. These antibodies protect the neonate 
against infections in the first months of life when the 
immune system is still immature and active immunity 
has not yet been acquired (10, 11). Additionally, efforts 
should be made to achieve a high immunization rate 
in the general population, especially in people having 
contact with young children and prospective parents 
(cocoon strategy) (10, 12). 
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Individuals with suspected or proven pertussis should 
avoid contact with infants and women in late preg-
nancy, especially with those who have not been immu-
nized, until five days of antibiotic treatment have been 
completed. Untreated patients should avoid contact 
with high-risk individuals for the full infectious period 
(1, 6). For hospitalized infected patients, droplet and 
contact isolation are mandatory to reduce the spread 
of the disease (6). In case of a pertussis outbreak in 
the hospital, under-vaccinated persons with contact to 
pertussis cases should be identified and a pertussis-
containing vaccine should be administered. Admit-
tedly, such vaccination might not prevent illness in a 
person who has already been infected with Bordetella 
pertussis. Generally, PEP is recommended depending 
on age and vaccination status. More detailed informa-
tion has been published by the Swiss Federal Office of 
Public Health (BAG) (13). PEP is always recommended 
for under-vaccinated exposed healthcare workers who 
have contact with high-risk patients (1, 6 ).
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Pertussis: summary of vaccination recommendations 
(toddler with high risk: infant attending childcare 
facilities, very low gestational age infants, all infants 
during pertussis outbreaks) (graphic designer:  
Chiara Benetton) (4).
Fig. 3 
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